Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
09/2003
09/30/2003US6627664 Administering perylenequinone derivative, and activating the derivative by exposing the perylenequinone to sound of a pre-determined frequency for therapy
09/30/2003US6627658 Administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, Lipoxin-A4, 15-epi-lipoxin4 or 15-R/S-methyl-lipoxin4 or salts, esters, amides, carboxylic acids or prodrugs to treat angiogenesis
09/30/2003US6627656 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
09/30/2003US6627652 Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
09/30/2003US6627637 I kappa B kinase inhibitors for treating various disorders including arthritis
09/30/2003US6627629 Useful for the treatment or prevention of asthma and other allergic diseases.
09/30/2003US6627626 Antiinflammation agents and antiarthritic agents colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
09/30/2003US6627405 53BP2 complexes
09/30/2003US6627200 Utilization of CD 137 in order to promote the proliferation of peripheral monocytes
09/30/2003US6627195 Binding agents to CD23
09/30/2003CA2133759C Evaluation and treatment of patients with progressive immunosuppression
09/25/2003WO2003078632A1 Novel receptor polypeptides and polynucleotides encoding the same
09/25/2003WO2003078465A1 The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
09/25/2003WO2003078435A1 Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
09/25/2003WO2003078425A1 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt
09/25/2003WO2003078421A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003078419A1 N-substituted benzothiophenesulfonamide derivative
09/25/2003WO2003078409A1 Carboxyoic acid compounds and drugs containing the compounds as the active ingredient
09/25/2003WO2003078404A1 Pyrimidine derivatives
09/25/2003WO2003078395A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003077951A1 Percutaneous absorption promoters and compositions for treating athlete’s foot
09/25/2003WO2003077947A1 Methods of modulating cd200 receptors
09/25/2003WO2003077941A1 Use of one or more natural or modified oxygen carriers, devoid of plasma and cellular membrane constituents, for externally treating open, in particular chronic wounds
09/25/2003WO2003077936A1 Cosmetic or pharmaceutical composition containing peptides
09/25/2003WO2003077935A1 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states
09/25/2003WO2003077919A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
09/25/2003WO2003077915A1 Use of rapamycin for inhibiting of cell death
09/25/2003WO2003077914A1 N3 alkylated benzimidazole derivatives as mek inhibitors
09/25/2003WO2003077911A1 Photodynamic therapy for pre-melanomas
09/25/2003WO2003077881A2 Method for production of phytoalexins
09/25/2003WO2003077861A2 Water-based delivery systems
09/25/2003WO2003077856A2 Lotion compositions
09/25/2003WO2003077847A2 Substituted amides
09/25/2003WO2003077840A2 Method of modulating inflammatory response
09/25/2003WO2003077832A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003WO2003077657A1 Choline-silicic acid complex with osmolytes and divalent trace elements
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003042411A3 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003029199A9 Benzene derivatives, process for preparing the same and use thereof
09/25/2003WO2003020239A3 Increase in the skin-moisturising properties of polyols
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2003013455A3 Cosmetic and dermatological light protective formulations containing benzotriazole derivatives and latex particles
09/25/2003WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof
09/25/2003WO2003002114A3 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
09/25/2003WO2002094287A3 Identifying parasitic fungi of the organism, and treatment thereof
09/25/2003WO2002080911A3 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
09/25/2003WO2002076410A3 Cosmetic and dermatological preparations comprising a content of a hop extract or hop-malt extract
09/25/2003WO2002074733A3 Tryptase-inhibitors
09/25/2003WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89)
09/25/2003WO2002062135A3 Scce modified transgenic mammals and their use as models of human disease
09/25/2003WO2002036573B1 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
09/25/2003WO2002028355A3 Methods and compositions for enhancing angiogenesis
09/25/2003WO2002020846A3 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
09/25/2003US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
09/25/2003US20030181519 Substituted phenyl naphthalenes as estrogenic agents
09/25/2003US20030181514 Therapeutic compounds and methods
09/25/2003US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
09/25/2003US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181481 Therapeutic drugs for treating central nervous system disorders
09/25/2003US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/25/2003US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
09/25/2003US20030181452 Inotropic agents such as (S)-N-tert-butyloxycarbonyl-N-methyl-tyrosyl)-4-(4-nitrophenyl)-piperazine, used for preventing and/or prophylaxis of diseases associated with adenosine 5'-triphosphate
09/25/2003US20030181443 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
09/25/2003US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents
09/25/2003US20030181439 Use of paullone derivatives for making medicines
09/25/2003US20030181438 Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
09/25/2003US20030181427 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
09/25/2003US20030181420 Modulators of LXR
09/25/2003US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire
09/25/2003US20030181386 Skin wound healing promoters
09/25/2003US20030181379 Novel fibroblast growth factor (FGF23) and methods for use
09/25/2003US20030181371 Compositions and methods of using collajolie
09/25/2003US20030181352 Substituted heterocyclic compounds
09/25/2003US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies
09/25/2003US20030180805 Methods and compositions for derepression of IAP-inhibited caspase
09/25/2003US20030180786 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
09/25/2003US20030180744 High affinity oligonucleotide ligands to growth factors
09/25/2003US20030180405 For cosmstics, drugs; antiinflamamtory agents; oxidation resistance
09/25/2003US20030180402 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia
09/25/2003US20030180390 Agent for reduction of scar formation by using wound alkalinization
09/25/2003US20030180339 Topical treatment of skin
09/25/2003US20030180331 Facilitation of wound healing with CM101/GBS toxin
09/25/2003US20030180306 Controlling cell differentiation; muscular disorders
09/25/2003US20030180300 Collagen biosynthesis; controlling cell differentiation, cell proliferation
09/25/2003US20030180288 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
09/25/2003US20030180287 Polypeptide formulation
09/25/2003US20030180275 Human serpin polypeptides
09/25/2003US20030180274 Skin disorders; bone defects; administering mixture of blood platelet and calcium phosphate
09/25/2003US20030180269 Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
09/25/2003US20030180265 Modulating angiogenesis
09/25/2003US20030180253 Stabilized liquid polypeptide-containing pharmaceutical compositions
09/25/2003US20030180246 Free-flowing anionic surfactant, alkanolamide and electrolytemixture
09/25/2003US20030180237 Compositions for skin lightening and toning down pigment disorders, comprising creatinine and/or creatinine derivatives as active substances
09/25/2003US20030180236 Resorcinol derivatives
09/25/2003US20030180231 Cosmetics, skin disorders; sunscreen agents; aging resistance
09/25/2003US20030180230 UV-photostabilized sunscreen compositions comprising dibenzoylmethane/triazine/benzophenone compounds
09/25/2003US20030180224 Photosensitisers
09/25/2003CA2488928A1 Method of modulating inflammatory response
1 ... 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 ... 1065